Literature DB >> 8147490

Dengue type-2 virus envelope protein made using recombinant baculovirus protects mice against virus challenge.

R Feighny1, J Burrous, R Putnak.   

Abstract

The gene coding for the envelope (E) glycoprotein of dengue-2 virus was cloned into baculovirus (Autographa californica nuclear polyhedrosis virus). The recombinant virus contained the entire E protein gene, preceded by 38 nucleotides from the end of the prematrix glycoprotein gene and followed by the first 83 nucleotides of nonstructural protein 1. When expressed in Spodoptera frugiperda (Sf9) cells, approximately 1 mg of recombinant E antigen was made per 10(9) cells. This antigen reacted with polyclonal, anti-dengue type-2 antibody and a dengue type-2-specific, neutralizing monoclonal antibody. BALB/c mice immunized with the recombinant antigen produced only non-neutralizing antibody against dengue-2 virus, but were partially protected against morbidity and mortality after intracranial challenge with virulent dengue-2 virus.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8147490     DOI: 10.4269/ajtmh.1994.50.322

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  4 in total

1.  Use of recombinant envelope proteins for serological diagnosis of Dengue virus infection in an immunochromatographic assay.

Authors:  A J Cuzzubbo; T P Endy; A Nisalak; S Kalayanarooj; D W Vaughn; S A Ogata; D E Clements; P L Devine
Journal:  Clin Diagn Lab Immunol       Date:  2001-11

2.  Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

Authors:  Soila Sukupolvi-Petty; S Kyle Austin; Michael Engle; James D Brien; Kimberly A Dowd; Katherine L Williams; Syd Johnson; Rebeca Rico-Hesse; Eva Harris; Theodore C Pierson; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

Review 3.  The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease.

Authors:  Beth-Ann G Coller; David E Clements; Andrew J Bett; Sangeetha L Sagar; Jan H Ter Meulen
Journal:  Vaccine       Date:  2011-07-21       Impact factor: 3.641

Review 4.  Vaccines for viral and parasitic diseases produced with baculovirus vectors.

Authors:  Monique M van Oers
Journal:  Adv Virus Res       Date:  2006       Impact factor: 9.937

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.